MedTrace Logo

Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

NCT00684671 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 506

Last updated 2018-08-17

Study results available
· View outcomes & findings →

Summary

Only subjects who participated in the primary study will be invited to participate in the extension phase and the challenge dose phase of this study.

Conditions

Interventions

BIOLOGICAL

Twinrix

Intramuscular injection, single dose in left deltoid.

BIOLOGICAL

Engerix-B

Intramuscular injection, single dose in left deltoid.

BIOLOGICAL

Havrix

Intramuscular injection, single dose in right deltoid.

BIOLOGICAL

HBVAXPRO

Intramuscular injection, single dose in the left deltoid.

BIOLOGICAL

Vaqta

Intramuscular injection, single dose in right deltoid.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
41 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-26
Primary Completion
2008-11-03
Completion
2008-11-03

Countries

  • Belgium
  • Czechia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00684671 on ClinicalTrials.gov